Company Overview and News
It has been about a month since the last earnings report for TCF Financial Corporation (TCF - Free Report) . Shares have added about 8.8% in that time frame.
TCB TCB.PRC TCB.PRB TCB-B TCF TCB.WS TCF.PRC TCF.PRD TCB-C UTX TCF.WS CR
On May 7, we issued an updated research report on TCF Financial Corporation (TCF - Free Report) . The company’s digitization efforts to meet customer requirements and solid organic growth indicate its upside potential. However, escalating expenses and declining fee income remain concerns.
TCB TCB.PRC TCB.PRB TCB-B TCF TCB.WS LAZ TCF.PRC TCF.PRD TCB-C TCF.WS CFR
TCF produced strong year-over-year revenue, earnings, and loan growth in a relatively more challenging quarter for many peer banks.
WFCNP TCB TCB.PRC TCB.PRB TCF WFC.PRL TCF.PRC TCF.PRD WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ TCB-B WFC.PRP WFC.PRO WFC.PRN TCB-C WFC.PRY WFC.PRX WFC.PRW WFC.PRV WFC WFC.WS CMA TCB.WS PNC TCF.WS
Shares of TCF Financial Corporation (TCF - Free Report) climbed 7.27% in single-day trading following the first-quarter 2018 earnings release on Apr 23, before the market opened. The company reported earnings per share of 39 cents, beating the Zacks Consensus Estimate of 37 cents. Further, the figure compared favorably with the prior-year quarter figure of 25 cents. Notably, results include non-recurring items of 2 cents per share associated with the redemption of perpetual preferred stock.
TCB TCB.PRC TCB.PRB TCF TCBI TCBIL TCF.PRC TCF.PRD TCBIW TCB-B TCB.WS TCBIP TCB-C TCF.WS
TCF Financial Corporation (NYSE:TCF) Q1 2018 Results Earnings Conference Call April 23, 2018 10:00 AM ET
WFCNP TCB TCB.PRC TCB.PRB DB TCF WFC.PRL TCF.PRC TCF.PRD WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ TCB-B WFC.PRP WFC.PRO WFC.PRN TCB-C WFC.PRY WFC.PRX WFC.PRW WFC.PRV WFC WFC.WS TCB.WS TCF.WS
Performances of most of the banks that released their first-quarter 2018 results till now were decent. Driven by higher rates and modest improvement in loan balances, banks reported an increase in their net interest income. Also, given the rebound in trading activities during the quarter, trading revenues improved. However, lower mortgage income and dismal investment banking performance adversely impacted overall fee income to some extent.
TCB TCB.PRC ZIONW TCB.PRB TCF BOH TCF.PRC TCF.PRD ZB.PRF ZB.PRA ZBK ZION ZB.PRG TCB-B ZB.PRH TCB.WS TCB-C TCF.WS ONB ZIONZ
With strong fundamentals and organic growth prospects, First Financial Bancorp. (FFBC - Free Report) appears to be an attractive pick now. In addition, interest rate hikes and improving economy are anticipated to further improve profitability. Analysts seem to be optimistic about the company’s prospects as the stock is witnessing upward estimate revisions. Over the past 60 days, the Zacks Consensus Estimate for the current year has risen nearly 1.
TCB TCB.PRC TCB.PRB TCF TCF.PRC FFBC TCF.PRD PRK FFBCW HTLF TCB-B TCB.WS VIRT THFF TCB-C TCF.WS
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to TCB / TCF Financial Corp. on message board site Silicon Investor.
as of ET